Thus, determining the molecular pathways that modify tau-mediated neurotoxicity will better our understanding of the pathology of all tauopathies, including Alzheimer's disease, and may uncover potential therapeutic targets. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.